A 32-year-old woman with severe immunosuppression (CD4 count 45 cells/μL) presents with cytomegalovirus (CMV) retinitis. She has previously received ganciclovir but developed resistance. Regarding antiviral agents for CMV, all of the following statements are correct EXCEPT:

Explanation

## CMV Antiviral Agents and Resistance Mechanisms ### Clinical Context: CMV Retinitis in Advanced AIDS CMV retinitis occurs almost exclusively in patients with CD4 counts <50 cells/μL. Treatment choice depends on: - Severity of infection - Renal function - Prior antiviral exposure and resistance - Immune recovery potential (immune reconstitution inflammatory syndrome risk) ### Analysis of Each Statement **Option 0 — Cidofovir (CORRECT)** - Acyclic nucleotide analogue (not a nucleoside) - **Does NOT require viral kinase activation** — directly phosphorylated by cellular kinases - Active against ganciclovir-resistant and foscarnet-resistant CMV - Intravenous administration; long intracellular half-life (17–65 hours) - Major toxicity: **nephrotoxicity** (requires aggressive hydration and probenecid) - Used for CMV retinitis when resistance develops **Option 1 — Foscarnet (CORRECT)** - Pyrophosphate analogue; inhibits viral DNA polymerase - **Does NOT require viral kinase activation** - Effective against ganciclovir-resistant CMV (UL97 or pol mutations) - Toxicities: - **Nephrotoxicity** (most common; requires hydration) - **Electrolyte abnormalities:** hypocalcemia, hypomagnesemia, hyperphosphatemia - Seizures (from electrolyte disturbances) - Genital ulceration - Requires **careful monitoring of renal function and electrolytes** — statement is TRUE **Option 3 — Valganciclovir (CORRECT)** - L-valine ester prodrug of ganciclovir - Rapidly hydrolyzed to ganciclovir in intestinal wall and liver - Achieves **60% bioavailability** (vs. 5–10% for oral ganciclovir) - Used for: - CMV retinitis maintenance therapy - CMV prophylaxis in transplant recipients (especially D+/R− and D+/R+) - CMV gastroenteritis or colitis - Oral administration is a major advantage for chronic suppression ### Incorrect Statement (Option 2 — CORRECT ANSWER) **Ganciclovir resistance mechanism — STATEMENT IS WRONG:** The statement claims: "Resistance typically develops through mutations in **viral DNA polymerase genes**." This is **INCOMPLETE and MISLEADING**. CMV ganciclovir resistance develops through TWO main pathways: 1. **UL97 kinase mutations** (~95% of resistant isolates) - UL97 is a viral protein kinase that phosphorylates ganciclovir to its monophosphate - Mutations in UL97 prevent ganciclovir activation - These mutants remain susceptible to foscarnet and cidofovir (which don't require UL97) 2. **Viral DNA polymerase (UL30) mutations** (~5% of resistant isolates) - Mutations reduce enzyme affinity for ganciclovir triphosphate - These mutants are resistant to ganciclovir, foscarnet, AND cidofovir ("multi-drug resistant") - Extremely rare **The critical error in Option 2:** It states resistance develops through "mutations in viral DNA polymerase genes" **as the typical mechanism**. In reality, **UL97 kinase mutations are the primary cause** (~95%), not DNA polymerase mutations. The statement reverses the frequency and importance of these two pathways. ### Comparative Table: CMV Antiviral Agents | Agent | Class | Kinase Required | Activation | Resistance | Toxicity | | --- | --- | --- | --- | --- | --- | | Ganciclovir | Nucleoside analogue | UL97 | UL97 → cellular kinases | UL97 mutations (95%) | Myelosuppression, neurotoxicity | | Valganciclovir | Prodrug of ganciclovir | UL97 | Hydrolysis → ganciclovir → UL97 | UL97 mutations | Myelosuppression | | Foscarnet | Pyrophosphate analogue | None | Direct inhibitor | Pol mutations (rare) | Nephrotoxicity, electrolyte abnormalities | | Cidofovir | Nucleotide analogue | None | Cellular kinases only | Pol mutations (rare) | Nephrotoxicity, uveitis | **Key Point:** CMV ganciclovir resistance is **primarily due to UL97 kinase mutations** (~95%), not DNA polymerase mutations. UL97-mutant strains remain susceptible to foscarnet and cidofovir. **High-Yield:** When ganciclovir-resistant CMV occurs, the next agents of choice are foscarnet or cidofovir — both bypass the need for UL97 kinase activation. If resistance to both occurs (rare), it indicates UL30 DNA polymerase mutations (multi-drug-resistant CMV). **Clinical Pearl:** In an AIDS patient with CMV retinitis and ganciclovir resistance, foscarnet is often preferred over cidofovir because cidofovir's long dosing interval (weekly) is less suitable for rapidly progressive retinitis, whereas foscarnet allows daily dosing for better viral suppression.